The most exciting advances in the tuberous sclerosis complex (TSC) field occurred in 1993 and 1997 with the cloning of the TSC2 and TSC1 genes, respectively, and in 2003 with the identification of Rheb as the target of tuberin's (TSC2) GTPase activating protein (GAP) domain. Rheb has a dual role: it activates mTOR and inactivates B-Raf. Activation of mTOR leads to increased protein synthesis through phosphorylation of p70S6K and 4E-BP1. Upon insulin or growth factor stimulation, tuberin is phosphorylated by several kinases, including AKT/PKB, thereby suppressing its GAP activity and activating mTOR. Phosphorylation of hamartin (TSC1) by CDK1 also negatively regulates the activity of the hamartin/tuberin complex. Despite these biochemical advances, exactly how mutations in TSC1 or TSC2 lead to the clinical manifestations of TSC is far from being understood. Two of the most unusual phenotypes in TSC are the apparent metastasis of benign cells carrying TSC1 and TSC2 mutations, resulting in pulmonary lymphangiomyomatosis, and the ability of cells with TSC1 or TSC2 mutations to differentiate into the separate components of renal angiomyolipomas (vessels, smooth muscle and fat). We will discuss how the TSC signaling pathways are affected by mutations in TSC1 or TSC2, focusing on how these mutations may lead to the renal and pulmonary manifestations of TSC. Oncogene (2005) 24, 7475-7481.
Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome with a wide spectrum of clinical manifestations, many of which are age-related. It often manifests in early age with infantile seizures and benign cerebral cortical tubers, and patients may have mental retardation and autism. Other brain lesions include subependymal nodules, subependymal giant cell astrocytomas (SEGAs) and retinal hamartomas. Patients often develop skin lesions, including facial angiofibromas, hypomelanotic macules, ungual fibromas and shagreen patches. In the kidney, benign angiomyolipomas and cysts occur frequently, and malignant angiomyolipomas and renal cell carcinomas are less common. The brain, skin, and renal manifestations are hallmarks of TSC and can be used as the basis for differential diagnosis. Brain and renal lesions cause the highest morbidity and mortality among TSC patients. Heart rhabdomyomas, often observed in infancy, spontaneously regress. A particularly striking manifestation of TSC is pulmonary lymphangiomyomatosis (LAM). It is observed exclusively in female TSC patients. LAM can also occur in women who do not have TSC (sporadic LAM). LAM is characterized by benign smooth muscle cell proliferation in the lungs, which thicken the alveolar wall and reduce gas exchange, and by cystic degeneration of the lungs, resulting in lung collapse. LAM patients often become oxygen-dependent.
The genetic basis of TSC
TSC is inherited as an autosomal dominant trait with very high penetrance, but only approximately 20% of the patients have positive family history of TSC. The majority of the remaining 80% represents de novo mutations in either TSC1 or TSC2. TSC2, which was cloned in 1993, has 41 exons and a 5.5 kb mRNA transcript (The European Chromosome 16 Tuberous Sclerosis Consortium, 1993). TSC1, which was cloned in 1997, consists of 21 coding exons (van Slegtenhorst et al., 1997) . The 8.6 kb mRNA transcript contains a small 5 0 and a large 4 kb 3 0 un-translated region. More than three hundred germline mutations have been reported for TSC2, including missense, nonsense, frameshift deletions/insertions and splice junction mutations (Au et al., 1998; Jones et al., 1999; Dabora et al., 2001; Sancak et al., 2005) . The most frequent TSC2 mutations are missense changes in codons 611 and 1675, and an 18-bp in-frame deletion in exon 40. However together they represent less than 5% of the known TSC2 mutations. Of the TSC2 mutations, 20% are missense or nonsense. In contrast, nearly all the reported TSC1 mutations are either nonsense or frameshift, causing premature protein truncation (Kwiatkowska et al., 1998; Jones et al., 1999; van Slegtenhorst et al., 1999; Sancak et al., 2005) . Although no significant genotype-phenotype correlations have been established, patients with TSC1 mutations are less severely affected than those with TSC2 mutations (Jones et al., 1999; Dabora et al., 2001) .
In agreement with Knudson's two-hit tumor suppressor gene model (Knudson, 1971) , inactivation of both alleles of either TSC1 or TSC2 is necessary at least for some of the clinical manifestations of TSC. Most 'second hits' are large deletions involving loss of surrounding loci. These mutations are referred to as loss-of-heterozygosity (LOH) since they affect neighboring heterozygous polymorphic markers. LOH in TSC1 or TSC2 has been observed in angiomyolipomas, rhabdomyomas and LAM cells (Carbonara et al., 1994; Green et al., 1994; Henske et al., 1995 Henske et al., , 1996 Smolarek et al., 1998) . LOH has not been consistently observed in cerebral cortical tubers (Henske et al., 1996; Niida et al., 2001) .
The protein products of TSC1 and TSC2 are hamartin and tuberin, respectively (Figure 1 ). Hamartin and tuberin physically interact to form heterodimers (Plank et al., 1998; van Slegtenhorst et al., 1998) . Hamartin and tuberin are expressed by the same cell types within multiple organs including the kidney, brain, lung and pancreas (Plank et al., 1999) . A definitive subcellular localization has not been established yet for either hamartin or tuberin. In most studies, hamartin and tuberin are diffusely cytoplasmic, although tuberin has been reported in the Golgi apparatus (Wienecke et al., 1996) and the nucleus (Lou et al., 2001) . It is not clear whether these differences reflect cell type or cell cycle-specific differential localization, or antibody nonspecificity.
Signaling pathways involving the TSC proteins
Hamartin and tuberin participate in the insulin/AKT/ mTOR signaling pathway
The first critical clues for the function of hamartin and tuberin came from genetic epistasis studies in Drosophila. Mutant cells for dTsc1 and dTsc2 (the Drosophila TSC1 and TSC2 homologues, respectively) exhibit increase in cell and organ size, phenotypes that are not rescued by insulin receptor (dinr) or dAkt mutants. However, dS6k mutants reverted the dTsc1 phenotype, suggesting that dTsc1/dTsc2 are epistatic to dinr and dAkt, and dS6k is epistatic to dTsc1/dTsc2 (Figure 2a ) (Gao and Pan, 2001; Potter et al., 2001) . Biochemical studies showed that mammalian tuberin is directly phosphorylated by AKT/protein kinase B (PKB) at two residues, S939 and T1462 (Dan et al., 2002; Manning et al., 2002; Potter et al., 2002) . The hamartin/tuberin complex acts upstream of the target of Rapamycin (TOR) in yeast, insects and mammals (Gao et al., 2002; Inoki et al., 2002; van Slegtenhorst et al., 2004) . Mammalian TOR (mTOR) is a serine-threonine kinase, which increases cell growth and proliferation through phosphorylation of two effector molecules: p70S6K and 4E-BP1. p70S6K is responsible for increased ribosome biogenesis through phosphorylation of the ribosomal protein S6. 4E-BP1 binds to eIF4E and inhibits the 5 0 cap-dependent mRNA translation (reviewed by Fingar and Blenis, 2004) . Loss of hamartin or tuberin results in TOR-dependent increased phosphorylation of the ribosomal protein S6, p70S6K and 4E-BP1 (Gao et al., 2002; Goncharova et al., 2002; Tee et al., 2002) .
Although a highly conserved GTPase activating protein (GAP)-related domain was identified in tuberin in 1993, it was not until 2003 that Rheb, a member of the Ras super-family, was identified as the specific GTPase downstream of tuberin (Garami et al., 2003; Inoki et al., 2003a) . Overexpression of Rheb leads to increased mTOR and S6 phosphorylation, which is blocked by the immunosuppressant drug Rapamycin (Castro et al., 2003; Garami et al., 2003; Stocker et al., 2003; Tee et al., 2003) . Several patient-derived TSC2 mutations were identified within the GAP domain (Maheshwar et al., 1997; Jones et al., 1999) . These mutants have low GAP activity toward Rheb (Li et al., (Hodges et al., 2001) and with ezrin-radixin-moesin through amino acids 881-1084 (Lamb et al., 2000) . It is phosphorylated by CDK1/cyclin B1 at residues T417, S584 and T1047, and by GSK3b at T357 and T390. (b) Tuberin (encoded by TSC2) is 1807 amino acids long with molecular mass 200 kDa. It interacts with hamartin through amino acids 1-418 (Hodges et al., 2001 ). It has a GTPase activating protein (GAP) domain with specificity for Rheb. It is phosphorylated by AKT/PKB (residues S939 and T1462), MK2 (S1210), RSK1 (S1798), AMPK (T1227 and S1345) and ERK2 (S664)
Regulation of cell growth and differentiation by the TSC genes A Astrinidis and EP Henske 2004) confirming that the GAP activity of tuberin is essential for its physiological function. Moreover, patient-derived TSC2 mutations that disrupt the association of tuberin with hamartin also have decreased GAP activity (Nellist et al., 2005b) , indicating that interaction with hamartin is important for tuberin's function as a GAP. This is consistent with the similar clinical phenotype of TSC1 and TSC2-associated disease.
Rheb inhibits B-Raf kinase -a Rapamycin-independent function
Two groups have demonstrated that Rheb directly binds and inhibits the kinase B-Raf (Im et al., 2002; Karbowniczek et al., 2004) . Stable or transient expression of tuberin increases the phosphorylation of p42/44 mitogen-activated protein kinase (MAPK) (Karbowniczek et al., 2004) . Tuberin inhibition by siRNA or expression of Rheb negatively regulates the B-Rafinduced phosphorylation of p42/44 MAPK in a Rapamycin-independent manner, indicating that the Rapamycin-sensitive mTOR complex is not involved in this process. These data indicate that Rheb has two separate growth-related functions: B-Raf inhibition and mTOR activation. These two opposing effects may counterbalance each other, naturally limiting Rheb's ability to induce tumor growth in cells expressing B-Raf, and contributing to the fact that the vast majority of tumors in TSC patients are benign. Since B-Raf expression is variable between cell types (Hagemann and Rapp, 1999) , it is likely that Rheb inhibits p42/44 MAPK activity in a cell type-specific manner. Whether Rheb inhibits other members of the Raf family (A-Raf and C-Raf/Raf1) is not known yet.
Tuberin integrates multiple mitogenic signals
AKT/PKB was the first kinase recognized to phosphorylate and inactivate tuberin upon insulin or growth factor stimulation. During the past 2 years, other kinases have also been found to regulate tuberin's function (Figure 1b ). These kinases include MK2, ribosomal S6 kinase 1 (RSK1), ERK2 and AMP kinase (AMPK). The phosphorylation of tuberin at residue S1210 by MAPK-activated protein kinase 2 (MK2) (Li et al., 2003) promotes binding of tuberin with 14-3-3 proteins, which may sequester tuberin from its physiological substrates. Tuberin interacts with and is phosphorylated by p90 RSK1 at S1798 (Roux et al., 2004) . This phosphorylation site is important for PMA-induced stimulation of p70S6K and its effect is additive to the phosphorylation by AKT at S939 and T1462. Inactivating phosphorylation of tuberin at residue S664 by ERK2 causes the disruption of the hamartin/tuberin complex and activation of mTOR. A single nonphosphorylatable tuberin mutant at this site inhibits tumorigenicity of a cell line with constitutively activated MAPK pathway (Ma et al., 2005) . All those phosphorylation events are inactivating and positively regulate the mTOR signaling pathway. In contrast, under energy deprivation, tuberin undergoes activating phosphorylation at T1227 and S1345 by AMPK, leading to enhanced inhibition of S6 (Inoki et al., 2003b) . This phosphorylation may protect the cells from apoptosis caused by prolonged energy deprivation.
It is likely that tuberin is the target of additional phosphorylation events. For example, tuberin is phosphorylated at S1395/1397 and S1775 by an unknown kinase (Nellist et al., 2005a) . The identification of novel phosphorylation sites and kinases will provide us with a more comprehensive understanding of the signaling pathways involved in the pathogenesis of the disease.
The potential of mTOR inhibition in TSC therapy
Since mTOR is directly activated upon loss of TSC1 or TSC2, Rapamycin has been identified as a potential therapeutic agent for TSC and LAM. Treatment of hamartin or tuberin null cells with Rapamycin (or the Rapamycin analogue CCI-779) results in apoptosis and decreased proliferation, and reduction of tumor size in the Eker rat model for TSC and in Tsc2 þ /À mice (Kenerson et al., 2002 Lee et al., 2005) . Rapamycin clinical trials for individuals with angiomyolipomas or pulmonary LAM are ongoing. (TSC2) and decreases the GAP activity toward Rheb. Rheb-GTP activates mTOR, which directly phosphorylates p70S6K and 4E-BP1, leading to increased S6 and eIF4E activity. The net result of mTOR activation is increased ribosome biogenesis (through S6) and increased 5 0 cap-dependent mRNA translation (through eIF4E). Rheb inhibits B-Raf activity by direct binding to B-Raf. A negative feedback loop from p70S6K to insulin receptor substrate (IRS1/2) is responsible for decreased AKT phosphorylation in hamartin and tuberin-null tumors. Additionally, tuberin is inactivated by phosphorylation from ERK2. (b) Hamartin and tuberin integrate growth factor, energy and cell cycle signals through multiple kinases. Tuberin inhibits Rheb to suppress mTOR and activate B-Raf, leading to control of cell growth and differentiation
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Several research groups made the observation that in tuberin-null cells, AKT is not efficiently phosphorylated after growth factor stimulation (Jaeschke et al., 2002; Kwiatkowski et al., 2002; Zhang et al., 2003) . This led to the identification of a negative feedback loop, which is responsible for the inactivation of AKT signaling downstream of insulin receptor substrate proteins, IRS1 and IRS2 (Figure 2a ) (reviewed by Manning, 2004) . The stability and phosphorylation of IRS1/2 is compromised in tuberin-null cells (Jaeschke et al., 2002; Harrington et al., 2004) and this is caused by direct phosphorylation of the IRS proteins by p70S6K (Harrington et al., 2004; Shah et al., 2004) . Rapamycin treatment restores insulin signaling toward AKT. This feedback inhibition of AKT signaling, raises the concern that long-term Rapamycin treatment may increase the risk of malignant tumors in TSC patient by reactivating AKT (Manning, 2004) .
What is the primary function of hamartin?
In contrast to these advances in understanding the function of tuberin, very little is known about the function of hamartin. The fact that patients with TSC1 or TSC2 mutations have similar clinical manifestations indicates that hamartin is essential to the function of tuberin. Hamartin could be responsible for the proper subcellular localization of tuberin or it could be required to activate tuberin's GAP domain perhaps by releasing an autoinhibitory domain. Hamartin is an interacting partner with members of the ezrin-radixin-moesin family (Lamb et al., 2000) and neurofilament-L (Haddad et al., 2002), suggesting that it may act as a scaffolding protein for proper localization of tuberin. Further evaluation of the subcellular localization of both hamartin and tuberin is needed.
Whether hamartin is important for the function of tuberin as a GAP is still controversial. Tee et al. (2003) . found that tuberin's in vitro GAP activity is enhanced by the presence of hamartin, and Nellist et al. (2005b) reported that mutations which disrupt the hamartin/ tuberin interaction decrease tuberin's GAP activity, while Li et al. (2004) concluded that tuberin's function in vivo is independent of hamartin.
Recent work from our group indicates that the activity of the hamartin/tuberin complex is regulated by hamartin phosphorylation. Hamartin is phosphorylated at three residues (T417, S584 and T1047) by the cyclin-dependent kinase 1 (CDK1) during nocodazoleinduced G 2 /M arrest and during progression of synchronized cells through G 2 /M phase of the cell cycle (Astrinidis et al., 2003) . This phosphorylation is evident at endogenous hamartin levels. Nonphosphorylatable hamartin mutants for the CDK1 sites inhibit p70S6K activity more potently than wild-type hamartin, suggesting that hamartin phosphorylation leads to decreased tuberin GAP activity during G 2 /M.
In addition to phosphorylation by CDK1, hamartin is the substrate of other kinases. GSK3b phosphorylates hamartin at residues T357 and T390 (Mak et al., 2005) . This phosphorylation increases the stability of the hamartin/tuberin complex causing attenuation of b-catenin signaling. Finally, hamartin is phosphorylated at residue S505 (Nellist et al., 2005a) , although the responsible kinase is unknown.
Links between signaling and clinical manifestations of TSC

Pulmonary manifestations of TSC -the 'benign metastasis' model
Hyperactivation of S6 and 4E-BP1 has been observed in LAM cells and angiomyolipomas from TSC patients (Goncharova et al., 2002; Kenerson et al., 2002; El-Hashemite et al., 2003b; Karbowniczek et al., 2003b) . Pulmonary LAM occurs in female TSC patients, and also in women without TSC (sporadic LAM). Approximately 60% of sporadic LAM patients have renal angiomyolipomas, and LAM cells are morphologically and immunohistochemically identical to the smooth muscle component of renal angiomyolipomas. Our group found the same TSC2 mutations in LAM and angiomyolipoma cells from sporadic LAM patients, but not in the peripheral blood, normal kidney or normal lung cells of the patients (Carsillo et al., 2000) , indicating that the LAM and angiomyolipoma cells are genetically identical and must arise from a common progenitor. Similar results were obtained from the study of Japanese sporadic LAM patients (Sato et al., 2002) . This led us to propose the 'benign metastasis' model for LAM pathogenesis, in which histologically benign cells with mutations in TSC1 or TSC2 have the ability to metastasize to the lungs from other organs (Carsillo et al., 2000) . Further evidence to support the benign metastasis model was obtained from analysis of recurrent LAM after lung transplantation, in which the same TSC2 mutation was present in native LAM and recurrent LAM cells after lung transplantation (Karbowniczek et al., 2003a) .
Biochemical and cellular data support the notion that cells lacking hamartin or tuberin have the ability to migrate aberrantly. Both hamartin and tuberin activate members of the Rho GTPase superfamily, which regulate the actin cytoskeleton, cell morphology and migration, and induce focal adhesions (Lamb et al., 2000; Astrinidis et al., 2002; Goncharova et al., 2004) . Tuberin-deficient smooth muscle cells exhibit increased migration in vitro, compared to cells with reintroduction of wild-type tuberin, and decreased RhoA-GTP (Astrinidis et al., 2002) . Tuberin expression increases the in vitro attachment of cells on plastic, consistent with decreased expression of focal adhesion kinase (FAK) and increase in the fraction of phospho-FAK (Astrinidis et al., 2002) . These findings are consistent with the hypothesis that tuberin-deficient cells have increased migratory potential. In 2004, Goncharova et al. (2004) showed that expression of full-length tuberin or the hamartin binding domain of tuberin results in Rac1 activation and decreases the activation of RhoA. These results contradict our finding that, upon tuberin expression, the activity of Rac1 does not change and that RhoA is strongly activated (Astrinidis et al., 2002) , and may reflect differences in the experimental approaches in the two papers; stable retroviral reintroduction (Astrinidis et al., 2002) versus transient overexpression of tuberin (Goncharova et al., 2004) .
In 2004, the groups of Sabatini and Hall found that shRNA or siRNA inhibition of mTOR or rictor, a novel interacting partner of mTOR, induces formation of actin stress fibers and focal adhesions (Jacinto et al., 2004; Sarbassov et al., 2004) . These results are consistent with the finding that hamartin expression induces formation of stress fibers and focal adhesions (Lamb et al., 2000) . Rictor forms a complex with mTOR and GbL (Jacinto et al., 2004; Sarbassov et al., 2004) , which is distinct from the Rapamycin-sensitive mTOR/GbL/ raptor complex (Kim et al., 2003) . Whether mTOR/ rictor is regulated by the hamartin/tuberin complex, and whether Rheb mediates the hamartin/tuberin-dependent changes in the cytoskeleton, is unknown. Also, the relevance of patient-derived TSC2 mutations with respect to the aforementioned changes has not been studied yet.
The fact that pulmonary LAM occurs only in women has led to the hypothesis that estrogen regulates TSC signaling. Consistent with this hypothesis, pulmonary LAM and angiomyolipoma cells from LAM patients express estrogen and progesterone receptors (Kinoshita et al., 1995; Logginidou et al., 2000) . The carboxyterminus of tuberin interacts with estrogen receptor a (Henry et al., 1998; Finlay et al., 2004) and functions in vitro as a transcriptional corepressor of the estrogen receptor . The growth of cells with TSC2 mutations is stimulated by estradiol (Howe et al., 1995; Yu et al., 2004) , and re-expression of tuberin in tuberin-null cells abrogated estradiol-induced growth in vitro (Finlay et al., 2004) . York et al. (2005) recently showed that tuberin and estrogen receptor a interact at endogenous expression levels in multiple cell types. Whether the tuberin/estrogen receptor a interaction is disrupted by patient-derived TSC2 mutations, and how estrogen signaling might lead to LAM is not known.
Renal manifestations of TSC -aberrant differentiation of angiomyolipomas
The renal manifestations in TSC patients include both mesenchymal (angiomyolipomas) and epithelial (cysts, oncocytomas and carcinomas) tumors. This heterogeneity suggests that the hamartin/tuberin complex may regulate the epithelial-mesenchymal transition of progenitor renal cells (Henske, 2004) .
Angiomyolipomas are by far the most extensively studied renal manifestation of TSC. Angiomyolipomas have three distinct components: vessels, smooth muscle and fat cells. LOH at the TSC1 or TSC2 locus (Henske et al., 1995; Niida et al., 2001; Karbowniczek et al., 2003b) and hyperphosphorylation of S6 (El-Hashemite et al., 2003b; Karbowniczek et al., 2003b) have been observed in each of the three components of angiomyolipomas. This indicates that all three components arise from a common progenitor and suggests that the hamartin/tuberin complex regulates cellular differentiation. The vascular component of angiomyolipomas consists of five morphologically distinct types of vessels (Karbowniczek et al., 2003b) , four of which are neoplastic, with TSC2 LOH, and one of which is nonneoplastic. The finding that the hamartin/tuberin complex is required for mTOR inhibition during hypoxic conditions and that disruption of the complex increases hypoxia-induced factor 1 (HIF1) (Brugarolas et al., 2004) raises the possibility that the non-neoplastic vasculature of angiomyolipomas is partially a result of aberrant mTOR activity. Vascular endothelial growth factor expression is increased in primary renal cell carcinomas from Tsc2 þ /À Eker rats (Liu et al., 2003) , is secreted from Tsc1 and Tsc2 null mouse embryonic fibroblasts and is increased in the serum of Tsc1 þ /À mice (El-Hashemite et al., 2003a).
A new model for somatic inactivation -constitutive phosphorylation of tuberin
One intriguing aspect of TSC pathophysiology is that, in contrast to renal angiomyolipomas and pulmonary LAM, cortical tubers have not been shown to have LOH at either the TSC1 or TSC2 regions (Henske et al., 1996; Niida et al., 2001; Ramesh, 2003) . It is possible that a second hit genetic event is present only in certain cell types within a tuber. However, some groups proposed that constitutive phosphorylation and inactivation of tuberin might substitute for a genetic second hit (Govindarajan et al., 2003; Han et al., 2004; Ma et al., 2005) . Since second hit events can be very difficult to detect, particularly in tumors with both neoplastic and non-neoplastic components, whether this model actually contributes to any of the clinical manifestations of TSC is unknown.
The hamartin/tuberin complex as a nexus for cell growth signaling and the future of TSC research
The hamartin/tuberin complex appears to integrate growth factor, energy, nutrient and cell cycle cues to regulate cell growth and differentiation in an mTOR and B-Raf-dependent manner (Figure 2b) . The dysregulation of hamartin or tuberin, by genetic alterations or perhaps by inactivating phosphorylation, has devastating consequences in the homeostasis of cell growth and proliferation, as manifested by the development of TSC and LAM. The existence of negative feedback loops increases the complexity of these signaling pathways and may influence the development of targeted therapeutic strategies. Key priorities that will undoubtedly be at the forefront of basic TSC research are elucidating hamartin's function and its role in the localization and function of tuberin, determining whether Rheb is the sole downstream effector of the hamartin/tuberin complex, and determining whether the cytoskeletal changes observed in TSC cells are mediated by the Rapamycin-insensitive mTOR/rictor complex. In addition, there are many areas of uncertainty regarding the pathogenesis of the renal and pulmonary manifestations of TSC. The role of estrogen in LAM pathogenesis, the cellular basis of the 'benign metastasis' model of LAM cells, and the pathways through which the TSC proteins regulate cellular differentiation in angiomyolipomas, need to be elucidated. The short and long-term impact of Rapamycin therapy in TSC and LAM is unknown. Finally, the development of animal models that recapitulate the most clinically significant tumors and symptoms of TSC will be critical for progress toward targeted therapeutic approaches.
